Your browser doesn't support javascript.
loading
Immune checkpoint inhibitors: a new frontier in bladder cancer.
Kates, Max; Sopko, Nikolai A; Matsui, Hotaka; Drake, Charles G; Hahn, Noah M; Bivalacqua, Trinity J.
Afiliação
  • Kates M; The James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, 1800 Orleans Street, Marburg 420, Baltimore, MD, 21287, USA. mkates@jhmi.edu.
  • Sopko NA; Department of Urology, The Johns Hopkins School of Medicine, 1800 Orleans Street, Marburg 420, Baltimore, MD, 21287, USA. mkates@jhmi.edu.
  • Matsui H; The James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, 1800 Orleans Street, Marburg 420, Baltimore, MD, 21287, USA.
  • Drake CG; Department of Urology, The Johns Hopkins School of Medicine, 1800 Orleans Street, Marburg 420, Baltimore, MD, 21287, USA.
  • Hahn NM; The James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, 1800 Orleans Street, Marburg 420, Baltimore, MD, 21287, USA.
  • Bivalacqua TJ; Department of Urology, The Johns Hopkins School of Medicine, 1800 Orleans Street, Marburg 420, Baltimore, MD, 21287, USA.
World J Urol ; 34(1): 49-55, 2016 Jan.
Article em En | MEDLINE | ID: mdl-26487055
Immunotherapy is rapidly changing the field of urologic oncology. In this review, we discuss the role of the immune system in general and place a particular emphasis on the biology of the immune checkpoint and its role in cancer. Bladder cancer, as one of the most immunogenic neoplasms, is an exciting target for immune checkpoint inhibition. Early preclinical data and human trial experience suggest that this new drug class may shape bladder cancer therapy for years to come.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição / Anticorpos Monoclonais Humanizados / Anticorpos Monoclonais / Antineoplásicos Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição / Anticorpos Monoclonais Humanizados / Anticorpos Monoclonais / Antineoplásicos Idioma: En Ano de publicação: 2016 Tipo de documento: Article